Sign in
Taking people in United StatesPhase 1

Studies how the drug NNC0721-8060 works in adults with overweight or obesity

Checks whether the drug NNC0721-8060 is safe in adults with overweight or obesity.

Key facts

Who runs it
Novo Nordisk A/S
Where
Lenexa and San Antonio, United StatesSee the 2 sites
Trial code
Registry title
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Status
Recruiting
Phase
Phase 1
People taking part
142 people, planned
Started
12 Aug 2026
Expected to end
23 Sept 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • NNC0721-8060
  • Semaglutide
  • Placebo
Record updated
4 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-55 who are living with overweight, to test how safe NNC0721-8060 is and how it works.

Age
18-55 years, both ages included.
Sex
Men and women (sex at birth).
Disease stage
Overweight with a Body Mass Index (BMI) of 27.0-34.9 kg/m^2, due to excess fat tissue as judged by the investigator.
Earlier treatment
No investigational medicine within 30 days or five half-lives (whichever is longer) before screening.
Biomarker or test result
HbA1c must be below 6.5 % (48 mmol/mol) at screening.

Main reasons for not taking part

  • Known or suspected allergy to the study treatment or related products
  • History of allergies (except seasonal allergies) or anaphylactic reactions
  • Pregnant, breastfeeding, planning pregnancy, or of childbearing potential without adequate contraception
  • Taking part in another interventional clinical study
  • HbA1c of 6.5 % (48 mmol/mol) or higher at screening

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male or female (sex at birth)
  • Age 18-55 years (both inclusive) at the time of signing informed consent
  • Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator
  • Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator

Who cannot take part

  • Previous randomisation in this study
  • Known or suspected hypersensitivity to study intervention(s) or related products
  • History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions
  • Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol
  • Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole [mmol/mol]) at screening
  • Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception
  • Current participation (signed informed consent) in any other interventional clinical study
  • Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • ICON Early Phase Services, LLCLenexa, United StatesContact: Novo NordiskTaking people
  • ICONSan Antonio, United StatesContact: Novo NordiskNot yet recruiting

About the trial

What the trial wants to find out

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

The 3 groups in the trial

  • NNC0721-8060Treatment being tested

    Participants will receive subcutaneous injection of NNC0721-8060.

  • SemaglutideExisting treatment, for comparison

    Participants will receive subcutaneous injection of semaglutide.

  • PlaceboPlacebo, for comparison

    Participants will receive subcutaneous injection of placebo.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
Plain-language title
Studies how the drug NNC0721-8060 works in adults with overweight or obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07767175, who can take part
Record updated
4 September 2026